BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 30632847)

  • 21. Alternative algorithm for L-asparaginase allergy in children with acute lymphoblastic leukemia.
    Soyer OU; Aytac S; Tuncer A; Cetin M; Yetgin S; Sekerel BE
    J Allergy Clin Immunol; 2009 Apr; 123(4):895-9. PubMed ID: 19081614
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prolonged first-line PEG-asparaginase treatment in pediatric acute lymphoblastic leukemia in the NOPHO ALL2008 protocol-Pharmacokinetics and antibody formation.
    Tram Henriksen L; Gottschalk Højfeldt S; Schmiegelow K; Frandsen TL; Skov Wehner P; Schrøder H; Klug Albertsen B;
    Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28660740
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Therapeutic alternatives to native L-asparaginase in the treatment of adult acute lymphoblastic leukemia].
    Thomas X; Cannas G; Chelghoum Y; Gougounon A
    Bull Cancer; 2010 Sep; 97(9):1105-17. PubMed ID: 20693115
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Asparaginase Erwinia chrysanthemi (Erwinaze®): a guide to its use in acute lymphoblastic leukemia in the USA.
    Keating GM
    BioDrugs; 2013 Aug; 27(4):413-8. PubMed ID: 23794007
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia.
    Hawkins DS; Park JR; Thomson BG; Felgenhauer JL; Holcenberg JS; Panosyan EH; Avramis VI
    Clin Cancer Res; 2004 Aug; 10(16):5335-41. PubMed ID: 15328169
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Polyethylene Glycol-conjugated L-asparaginase versus native L-asparaginase in combination with standard agents for children with acute lymphoblastic leukemia in second bone marrow relapse: a Children's Oncology Group Study (POG 8866).
    Kurtzberg J; Asselin B; Bernstein M; Buchanan GR; Pollock BH; Camitta BM
    J Pediatr Hematol Oncol; 2011 Dec; 33(8):610-6. PubMed ID: 22042277
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Asparaginase therapy in patients with acute lymphoblastic leukemia: expert opinion on use and toxicity management.
    Sandley M; Angus J
    Leuk Lymphoma; 2023 Apr; 64(4):776-787. PubMed ID: 36781296
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics and drug monitoring of L-asparaginase treatment.
    Boos J
    Int J Clin Pharmacol Ther; 1997 Mar; 35(3):96-8. PubMed ID: 9088996
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Managing hypersensitivity to asparaginase in pediatrics, adolescents, and young adults.
    Shinnick SE; Browning ML; Koontz SE
    J Pediatr Oncol Nurs; 2013; 30(2):63-77. PubMed ID: 23380527
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pegaspargase: an alternative?
    Holle LM
    Ann Pharmacother; 1997 May; 31(5):616-24. PubMed ID: 9161659
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation.
    van der Sluis IM; Vrooman LM; Pieters R; Baruchel A; Escherich G; Goulden N; Mondelaers V; Sanchez de Toledo J; Rizzari C; Silverman LB; Whitlock JA
    Haematologica; 2016 Mar; 101(3):279-85. PubMed ID: 26928249
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Population Pharmacokinetics to Model the Time-Varying Clearance of the PEGylated Asparaginase Oncaspar
    Würthwein G; Lanvers-Kaminsky C; Hempel G; Gastine S; Möricke A; Schrappe M; Karlsson MO; Boos J
    Eur J Drug Metab Pharmacokinet; 2017 Dec; 42(6):955-963. PubMed ID: 28349335
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anaphylactic reaction to polyethylene-glycol conjugated-asparaginase: premedication and desensitization may not be sufficient.
    Sahiner UM; Yavuz ST; Gökce M; Buyuktiryaki B; Altan I; Aytac S; Tuncer M; Tuncer A; Sackesen C
    Pediatr Int; 2013 Aug; 55(4):531-3. PubMed ID: 23910807
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The use of Erwinia asparaginase for adult patients with acute lymphoblastic leukemia after pegaspargase intolerance.
    Horvat TZ; Pecoraro JJ; Daley RJ; Buie LW; King AC; Rampal RK; Tallman MS; Park JH; Douer D
    Leuk Res; 2016 Nov; 50():17-20. PubMed ID: 27631159
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Successful challenges using native E. coli asparaginase after hypersensitivity reactions to PEGylated E. coli asparaginase.
    Fernandez CA; Stewart E; Panetta JC; Wilkinson MR; Morrison AR; Finkelman FD; Sandlund JT; Pui CH; Jeha S; Relling MV; Campbell PK
    Cancer Chemother Pharmacol; 2014 Jun; 73(6):1307-13. PubMed ID: 24771103
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hypersensitivity reactions to L-asparaginase do not impact on the remission duration of adults with acute lymphoblastic leukemia.
    Larson RA; Fretzin MH; Dodge RK; Schiffer CA
    Leukemia; 1998 May; 12(5):660-5. PubMed ID: 9593262
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Human Leucocyte Antigen alleles associated with asparaginase hypersensitivity in childhood Acute Lymphoblastic Leukemia patients treated with Pegylated asparaginase within Dana Farber Cancer Institute treatment protocols.
    Kondyli M; Tremblay DÉ; Rezgui A; Serfaty SA; Gagné V; Ribère M; Laverdière C; Leclerc JM; Tran TH; Sinnett D; Krajinovic M
    Leuk Res; 2021 Oct; 109():106650. PubMed ID: 34198115
    [No Abstract]   [Full Text] [Related]  

  • 38. [Advances on the role of pegaspargase in the treatment of childhood leukemia].
    Liu L; Xie XT
    Zhongguo Dang Dai Er Ke Za Zhi; 2014 Feb; 16(2):155-60. PubMed ID: 24568909
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hypersensitivity to Pegylated E.coli asparaginase as first-line treatment in contemporary paediatric acute lymphoblastic leukaemia protocols: a meta-analysis of the Ponte di Legno Toxicity working group.
    Brigitha LJ; Fiocco M; Pieters R; Albertsen BK; Escherich G; Lopez-Lopez E; Mondelaers V; Vora A; Vrooman L; Schmiegelow K; van der Sluis IM;
    Eur J Cancer; 2022 Feb; 162():65-75. PubMed ID: 34954438
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Allergic reactions and antiasparaginase antibodies in children with high-risk acute lymphoblastic leukemia: A children's oncology group report.
    Ko RH; Jones TL; Radvinsky D; Robison N; Gaynon PS; Panosyan EH; Avramis IA; Avramis VI; Rubin J; Ettinger LJ; Seibel NL; Dhall G
    Cancer; 2015 Dec; 121(23):4205-11. PubMed ID: 26308766
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.